Phase 1 Trial of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously with Concurrent Cisplatin and Radiation Therapy in Patients with Locoregionally Advanced Head-and-Neck Carcinoma
L. K. Mell,Y. A. Yu,K. T. Brumund,S. J. Advani,S. Onyeama,G. A. Daniels,R. A. Weisman,P. Martin,A. A. Szalay
DOI: https://doi.org/10.1016/j.ijrobp.2013.11.054
2014-01-01
Abstract:Purpose/Objective(s)To determine the safety of GL-ONC1, an attenuated vaccinia virus, delivered intravenously with concurrent chemoradiation therapy to patients with primary stage III-IVB head and neck cancer.Materials/MethodsThe population included patients with locoregionally advanced unresected stage III-IVB carcinoma of the head/neck, excluding stage III-IVA HPV-positive oropharyngeal cancers. The study design was a 3+3 phase 1 dose escalation trial. Chemoradiation therapy was given in 33-35 fractions of 2.00-2.12 Gy daily using IMRT with concurrent cisplatin 100 mg/m2 given days 1, 22, and 43. Escalating doses of GL-ONC1 were given as follows: cohort 1: 3x108 pfu given day 3; cohort 2: 1x109 pfu given day 3; cohort 3: 3x109 pfu given day 3; cohort 4: 3x109 pfu given days 3 and 8. Dose-limiting toxicity (DLT) was defined as grade ≥ 4 toxicity or grade ≥ 3 mucositis or skin reaction within radiation portals persisting > 6 weeks after chemoradiation therapy. (ClinicalTrials.gov Identifier: NCT01584284)ResultsBetween June 2012 and July 2013, 16 patients consented. 12 patients were enrolled, with 4 screen failures. 9 patients have completed chemoradiation therapy, with 11 currently assessable for dose-limiting toxicity (DLT). Median age was 57 years. 10 patients had stage IVA disease and 2 had stage IVB. 4 patients had primary of the hypopharynx, 3 larynx, 2 oropharynx, 1 nasopharynx, 1 paranasal sinus (PNS), and 1 unknown primary. Three tumors (25%) were p16-positive. No DLT has been encountered at any dose level. Adverse events deemed related to GL-ONC1 include grade 2 rigors (1 patient) and grade 1 rash (3 patients). In 1 patient, the rash was confirmed as viral in origin by fluorescence imaging and viral plaque assay. In 3 patients, viral presence in tumor was confirmed on mid-treatment biopsy by qPCR for A21L gene. Serious adverse events deemed unlikely to be related to GL-ONC1 were pulmonary embolism (1 patient), acute myocardial infarction (1 patient), grade 3 emesis (1 patient), and grade 3 neutropenia (1 patient). Of 9 patients completing therapy, 6 completed all 3 cycles of cisplatin, 3 completed 2 cycles, and 1 patient required a treatment break longer than 7 days. 7 patients have completed follow-up imaging. With median follow-up of 5 months, 6 patients had no evidence of disease. 1 patient with T4b adenoid cystic carcinoma of the PNS had persistent disease.ConclusionsDelivery of GL-ONC1 is safe and feasible in patients with advanced head/neck cancer undergoing standard chemoradiation therapy. Further study is needed to determine the optimal dosing schedule for phase 2 testing. Purpose/Objective(s)To determine the safety of GL-ONC1, an attenuated vaccinia virus, delivered intravenously with concurrent chemoradiation therapy to patients with primary stage III-IVB head and neck cancer. To determine the safety of GL-ONC1, an attenuated vaccinia virus, delivered intravenously with concurrent chemoradiation therapy to patients with primary stage III-IVB head and neck cancer. Materials/MethodsThe population included patients with locoregionally advanced unresected stage III-IVB carcinoma of the head/neck, excluding stage III-IVA HPV-positive oropharyngeal cancers. The study design was a 3+3 phase 1 dose escalation trial. Chemoradiation therapy was given in 33-35 fractions of 2.00-2.12 Gy daily using IMRT with concurrent cisplatin 100 mg/m2 given days 1, 22, and 43. Escalating doses of GL-ONC1 were given as follows: cohort 1: 3x108 pfu given day 3; cohort 2: 1x109 pfu given day 3; cohort 3: 3x109 pfu given day 3; cohort 4: 3x109 pfu given days 3 and 8. Dose-limiting toxicity (DLT) was defined as grade ≥ 4 toxicity or grade ≥ 3 mucositis or skin reaction within radiation portals persisting > 6 weeks after chemoradiation therapy. (ClinicalTrials.gov Identifier: NCT01584284) The population included patients with locoregionally advanced unresected stage III-IVB carcinoma of the head/neck, excluding stage III-IVA HPV-positive oropharyngeal cancers. The study design was a 3+3 phase 1 dose escalation trial. Chemoradiation therapy was given in 33-35 fractions of 2.00-2.12 Gy daily using IMRT with concurrent cisplatin 100 mg/m2 given days 1, 22, and 43. Escalating doses of GL-ONC1 were given as follows: cohort 1: 3x108 pfu given day 3; cohort 2: 1x109 pfu given day 3; cohort 3: 3x109 pfu given day 3; cohort 4: 3x109 pfu given days 3 and 8. Dose-limiting toxicity (DLT) was defined as grade ≥ 4 toxicity or grade ≥ 3 mucositis or skin reaction within radiation portals persisting > 6 weeks after chemoradiation therapy. (ClinicalTrials.gov Identifier: NCT01584284) ResultsBetween June 2012 and July 2013, 16 patients consented. 12 patients were enrolled, with 4 screen failures. 9 patients have completed chemoradiation therapy, with 11 currently assessable for dose-limiting toxicity (DLT). Median age was 57 years. 10 patients had stage IVA disease and 2 had stage IVB. 4 patients had primary of the hypopharynx, 3 larynx, 2 oropharynx, 1 nasopharynx, 1 paranasal sinus (PNS), and 1 unknown primary. Three tumors (25%) were p16-positive. No DLT has been encountered at any dose level. Adverse events deemed related to GL-ONC1 include grade 2 rigors (1 patient) and grade 1 rash (3 patients). In 1 patient, the rash was confirmed as viral in origin by fluorescence imaging and viral plaque assay. In 3 patients, viral presence in tumor was confirmed on mid-treatment biopsy by qPCR for A21L gene. Serious adverse events deemed unlikely to be related to GL-ONC1 were pulmonary embolism (1 patient), acute myocardial infarction (1 patient), grade 3 emesis (1 patient), and grade 3 neutropenia (1 patient). Of 9 patients completing therapy, 6 completed all 3 cycles of cisplatin, 3 completed 2 cycles, and 1 patient required a treatment break longer than 7 days. 7 patients have completed follow-up imaging. With median follow-up of 5 months, 6 patients had no evidence of disease. 1 patient with T4b adenoid cystic carcinoma of the PNS had persistent disease. Between June 2012 and July 2013, 16 patients consented. 12 patients were enrolled, with 4 screen failures. 9 patients have completed chemoradiation therapy, with 11 currently assessable for dose-limiting toxicity (DLT). Median age was 57 years. 10 patients had stage IVA disease and 2 had stage IVB. 4 patients had primary of the hypopharynx, 3 larynx, 2 oropharynx, 1 nasopharynx, 1 paranasal sinus (PNS), and 1 unknown primary. Three tumors (25%) were p16-positive. No DLT has been encountered at any dose level. Adverse events deemed related to GL-ONC1 include grade 2 rigors (1 patient) and grade 1 rash (3 patients). In 1 patient, the rash was confirmed as viral in origin by fluorescence imaging and viral plaque assay. In 3 patients, viral presence in tumor was confirmed on mid-treatment biopsy by qPCR for A21L gene. Serious adverse events deemed unlikely to be related to GL-ONC1 were pulmonary embolism (1 patient), acute myocardial infarction (1 patient), grade 3 emesis (1 patient), and grade 3 neutropenia (1 patient). Of 9 patients completing therapy, 6 completed all 3 cycles of cisplatin, 3 completed 2 cycles, and 1 patient required a treatment break longer than 7 days. 7 patients have completed follow-up imaging. With median follow-up of 5 months, 6 patients had no evidence of disease. 1 patient with T4b adenoid cystic carcinoma of the PNS had persistent disease. ConclusionsDelivery of GL-ONC1 is safe and feasible in patients with advanced head/neck cancer undergoing standard chemoradiation therapy. Further study is needed to determine the optimal dosing schedule for phase 2 testing. Delivery of GL-ONC1 is safe and feasible in patients with advanced head/neck cancer undergoing standard chemoradiation therapy. Further study is needed to determine the optimal dosing schedule for phase 2 testing.